Return to Clinical Trials Search Results

Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma

Primary Endpoint: To identify a gene expression and/or mutational profile that can separate primary cSCC tumors that have a high risk of recurrence compared to primary cSCC tumors that have a low risk of recurrence using RT-PCR and RNA sequencing (RNASeq). Secondary Endpoint: To validate the molecular profile with one or more independent patient populations. Long-term objective: To develop and validate the prognostic accuracy of a gene expression profile and/or mutational assay designed to predict the risk of recurrence associated with primary cSCC tumors.

Primary Endpoint: To identify a gene expression and/or mutational profile that can separate primary cSCC tumors that have a high risk of recurrence compared to primary cSCC tumors that have a low risk of recurrence using RT-PCR and RNA sequencing (RNASeq). Secondary Endpoint: To validate the molecular profile with one or more independent patient populations. Long-term objective: To develop and validate the prognostic accuracy of a gene expression profile and/or mutational assay designed to predict the risk of recurrence associated with primary cSCC tumors.